for the US Acute Liver Failure Study Group Acetaminophen (APAP)-induced acute liver failure (ALF) is associated with significant mortality. Traditional prognostic scores lack sensitivity. Serum liver-type fatty acid binding protein (FABP1) early (day 1) or late (day 3-5) levels are associated with 21-day mortality in the absence of liver transplant. Serum samples from 198 APAP-ALF patients (nested case-control study with 99 survivors, 99 nonsurvivors) were analyzed by enzyme-linked immunosorbent assay with clinical data from the US Acute Liver Failure Study Group registry (1998Group registry ( -2014. APAP-ALF survivors had significantly lower serum FABP1 levels early (238.6 versus 690.8 ng/mL, P < 0.0001) and late (148.4 versus 612.3 ng/mL, P < 0.0001) compared with nonsurvivors. FABP1 > 350 ng/mL was associated with significantly higher risk of death at early (P 5 0.0004) and late (P < 0.0001) time points. Increased serum FABP1 early (log FABP1 odds ratio 5 1.31, P 5 0.027) and late (log FABP1 odds ratio 5 1.50, P 5 0.005) were associated with significantly increased 21-day mortality after adjusting for significant covariates (Model for End-Stage Liver Disease, vasopressor use). Areas under the receiver operating characteristic curve for early and late multivariable models were 0.778 and 0.907, respectively. The area under the receiver operating characteristic curve of the King's College criteria (early, 0.552 alone, 0.711 with FABP1; late, 0.604 alone, 0.797 with FABP1) and the Acute Liver Failure Study Group prognostic index (early, 0.686 alone, 0.766 with FABP1; late, 0.711 alone, 0.815 with FABP1) significantly improved with the addition of FABP1 (P < 0.002 for all). Conclusion: In patients with APAP-ALF, FABP1 may have good potential to discriminate survivors from nonsurvivors and may improve models currently used in clinical practice; validation of FABP1 as a clinical prediction tool in APAP-ALF warrants further investigation. (HEPATOLOGY 2017;65:938-949) 
subsequent studies that have used KCC have shown relatively poor sensitivity of the APAP criteria, ranging 25%-76%. (3, (6) (7) (8) (9) More recently, the Acute Liver Failure Study Group (ALFSG) prognostic index also demonstrated limited sensitivity (41%) in APAP-ALF. (9) Liver transplant (LT) in APAP-ALF presents significant challenges due to the rapidity and severity of illness (i.e., high risk of cerebral edema and multiorgan failure), the potential for recovery without LT, and the presence of concomitant complex psychosocial issues (contraindications) in several patients. (10) (11) (12) Given advances in critical care management of ALF, some patients may have a good outcome despite meeting KCC and potentially could avoid unnecessary LT in the presence of improved prognostic markers or scores. (7, 13) Fatty acid-binding proteins (FABPs) are small (<15 kDa) cytoplasmic proteins that are abundantly expressed in tissues with active fatty acid metabolism, including hepatocytes. The primary function of FABPs is the intracellular transport of long-chain fatty acids. (14) The cellular expression of FABPs is responsive to changes in lipid metabolism, which can be induced by pathophysiological conditions such as ischemia/inflammation. (15) Liver-type FABP (FABP1), significantly expressed in hepatocytes, enterocytes, and to a lesser degree in renal tubular cells, has been associated with liver injury. (16) Serum levels of FABP1 have been found to be elevated in patients with hepatocyte injury secondary to alcohol or drug toxicity. (17) To date there are no published investigations on the role of FABP1 as a biomarker in patients with ALF. Serum FABP1 may have relevance in ALF given the severity of hepatic injury and the potential for recovery in the absence of transplant, particularly in APAP-ALF.
This nested case-control study of randomly selected samples from prospectively enrolled patients from the ALFSG registry examined levels of FABP1 in APAP-ALF patients. Specifically, our primary objectives were to test the following hypotheses:
1. Higher FABP1 serum levels are significantly associated with 21-day mortality (in the absence of transplant). 2. A threshold value of FABP1 is significantly associated with 21-day mortality. 3. Elevated serum levels of FABP1 in APAP-ALF are significantly associated with 21-day mortality after adjusting for other significant covariates. 4. The addition of FABP1 improves the performance of previously described prognostic models in APAP-ALF (KCC, ALFSG prognostic index).
Patients and Methods

STUDY DESIGN
This was a nested case-control study of prospectively collected data and biosamples of 198 patients enrolled in the ALFSG registry/biorepository and is outlined in detail in Supporting Fig. S1 . Between January 1998 and December 2014, 1,027 APAP-ALF patients were enrolled in the registry. Of these, 704 patients were alive at day 21 in the absence of LT. We identified 124 survivors who had early and late serum samples for analysis, of which 99 were randomly selected for analysis. Of 224 patients who died in the absence of LT, 87 had early and late samples (all were included in this analysis). A further 12 patients with an early sample (of a possible 92) were randomly selected for inclusion in this analysis. Random selection of patients was performed by personnel not involved in the analysis of the samples or statistical analysis for the report. All enrolling centers were tertiary academic centers, and all but one were LT centers. The institutional review board/health research ethics boards of all enrolling ALFSG sites have approved all research, and all clinical investigation has been conducted according to the principles expressed in the 1975 Declaration of Helsinki. Given that patients were unable to provide written consent (critical illness, hepatic encephalopathy [HE]), written assent was obtained from the next of kin from each patient. Each center implemented monitoring and therapeutic interventions according to institutional standards of care. All authors had access to the study data and reviewed and approved the final manuscript. Reporting of the analysis of this study followed the STROBE guidelines for reporting case-control studies. (18) Consistent with ALFSG studies, (19) the primary outcome was 21-day transplant-free survival (no patients received transplant in this analysis).
PARTICIPANTS
Inclusion criteria were as follows: (1) evidence of ALF according to the enrollment criteria for the ALFSG (see operational definitions), (2) age 18 years, (3) HE during the first 7 days of study admission (West Haven criteria), (20, 21) and (4) patients within the ALFSG registry with primary diagnoses of APAP determined by the site investigator. Exclusion criteria were as follows: 1) cirrhosis/acute on chronic liver failure, (2) patients without a primary diagnosis of APAP, and (3) patients who received LT. Serum samples were analyzed on study admission (early; day 1) and late (either day 3, 4, or 5 where available). None of the 198 APAP-ALF patients included received LT. Patients who received LT were excluded from our study because listing for transplant is a clinical decision which is not standardized among ALFSG sites. A further 51 healthy controls were analyzed (University of Alberta) for FABP1 only.
OPERATIONAL DEFINITIONS
For the purposes of this study, ALF was defined as international normalized ratio (INR) 1.5 and HE within the first 26 weeks of liver disease in a patient with an acute hepatic insult. (22) HE grade was defined by the West Haven criteria (simplified) as follows: grade 1, any alteration in mentation; grade 2, somnolent or obtunded but easily rousable or presence of asterixis; grade 3, rousable with difficulty; and grade 4, unresponsive to deep pain. (20, 21) In this study we defined "low coma grade" as grade 1 or 2 and "high coma grade" as grade 3 or 4. KCC 4 predicts poor outcome (death/transplant) if pH is < 7.3 or if INR is >6.5, creatinine is > 3.4 mg/dL, and coma grade is high (3 or 4) . The Model for End-Stage Liver Disease (MELD) is defined as 10 3 [0.957 3 log(4) 1 0.378 3 log(bilirubin) 1 1.12 3 log(INR)] for dialyzed patients and 10 3 [0.957 3 log(creatinine) 1 0.378 3 log (bilirubin) 1 1.12 3 log(INR)] for patients not dialyzed. (23) The ALFSG prognostic index calculates the log odds 
LABORATORY ASSAYS OF FABP1
FABP1 was measured in serum samples with a solid-phase enzyme-linked immunosorbent assay following the manufacturer's instructions (Biomatik). Briefly, samples were incubated for 2 hours on a monoclonal anti-FABP1 precoated plate. A specific FABP1 biotin-conjugated polyclonal antibody solution was added for 2 hours. After washing plates, avidin conjugated to horseradish peroxidase was added for 30 minutes. Finally, substrate tetramethylbenzidine was added for 15 minutes. Reactions were stopped by addition of sulfuric acid, and absorbance was read at 450 nm. The standard curve ranged from 1.56 ng/mL to 200 ng/mL. Samples were performed in duplicate and accepted as valid with a variation coefficient <25%.
CLINICAL VARIABLES
Clinical, biochemical, and outcome data were collected prospectively as part of the ALFSG registry to be analyzed for the 198 patients in this study. Data assessed in this study from the registry included demographic 
STATISTICAL METHODS
For differences between outcome groups (APAP-ALF survivors, n 5 99, APAP-ALF nonsurvivors, n 5 99), categorical variables were compared using the chi-squared test or Fisher's exact test (if n < 10 in any cell of the two by two table). FABP1 was treated as a continuous variable. Continuous variables were reported as medians with interquartile range and compared using the Wilcoxon rank sum test. Survival was defined as the dichotomous outcome, alive or dead at 21 days after enrollment into the registry (no patients received LT in this analysis). A two-sided P value < 0.05 was considered statistically significant for all comparisons.
In order to control for variables that may confound the effect of FABP1 on 21-day mortality, logistic regression analysis was performed. (24) Aside from FABP1, covariates considered in multivariable modeling included MELD, lactate, vasopressor use, RRT, MV, and high coma grade. Separate multivariable (logistic) regression models were derived for FABP1 early (day 1) and late (day 3-5) by including variables which were significant on univariate analysis and performing backward elimination with a P value threshold of 0.05. Model performance was assessed using the area under the receiver operating characteristic curve (AUROC) and the Hosmer Lemeshow test for goodness of fit. A bootstrap approach was implemented to validate parameter estimates and the AUROC from the multivariable regression analysis. Logistic regression was used to assess the significance of the addition of FABP1 to existing prognostic scores (KCC, ALFSG prognostic index). (9) Model performance (early and late) for KCC, ALFSG index, FABP1, FABP11KCC, and FABP11ALFSG index was assessed using AUROC statistics. Comparisons of AUROC statistics between models (e.g., KCC versus FABP11KCC) were made using the Delong method. (25) A threshold value of FABP1 associated with mortality was established based on maximizing the AUROC at both early and late time points. SAS software (version 9.3) was used for univariate comparisons and multivariable logistic regression modeling, and R software (version 3.1.2) was used for bootstrap analysis and development of graphs. (26) 
Results
COMPARATIVE ANALYSIS OF 198 APAP-ALF PATIENTS
Demographic and clinical outcomes stratified by mortality (alive at day 21, n 5 99; deceased, n 5 99) are shown in Table 1 . No patients in this analysis received LT. Comparing APAP-ALF survivors and nonsurvivors at day 21, there were no significant differences in age (35 versus 40, P 5 0.08) or gender (female, 76% versus 73%, P 5 0.63). Survivors required significantly less organ support during the 7 days of inpatient study (MV, 65% versus 93%; vasopressors, 12% versus 70%; RRT, 27% versus 45%). Survivors were less likely to achieve high (3 or 4) HE coma grade (62% versus 93%, P < 0.0001) and less likely to receive mannitol for intracranial hypertension (22% versus 46%, P 5 0.0003). APAP-ALF survivors were less likely to have complications during the first 7 days of study including seizures (3% versus 21%, P < 0.0001), arrhythmias (25% versus 38%, P 5 0.047), or gastrointestinal bleeding (8% versus 19%, P 5 0.037). On admission, 7% of APAP-ALF survivors and 16% of nonsurvivors met KCC (P 5 0.13).
Among the 99 APAP-ALF nonsurvivors, the most common causes of death reported were multiorgan failure (52%) and neurological complications (39%). Cause of death was unknown in 9% of cases.
CLINICAL PARAMETERS IN 198 APAP-ALF PATIENTS: ADMISSION (EARLY)
Comparisons of clinical parameters on study admission are shown in Table 2 . APAP-ALF survivors had significantly lower serum INR (2.7 versus 3.4), bilirubin (4.1 versus 5.0 mg/dL), creatinine (1.4 versus 2.6 mg/dL), and lactate (2.8 versus 7.0 mmol/L) levels compared to nonsurvivors (P < 0.003 for all comparisons). Survivors also demonstrated significantly lower MELD scores (23 versus 29, P < 0.0001) than nonsurvivors on admission. On study admission, survivors were significantly less likely to be on organ support (MV, 58% versus 80%, P 5 0.0007; vasopressors, 9% versus 42%, P < 0.0001) or to achieve high HE grade (57% versus 71%, P 5 0.034).
Admission (early) levels of FABP1 are shown in Table 2 and graphically in Fig. 1 . APAP-ALF survivors had significantly lower admission serum FABP1 levels (238.6 versus 690.8 ng/mL) compared with nonsurvivors (P < 0.0001). Plots of admission FABP1 and alanine aminotransferase (ALT) levels are also compared in Supporting Fig. S2 .
CLINICAL PARAMETERS IN 186 APAP-ALF PATIENTS: DAY 3-5 (LATE)
Comparisons of clinical parameters on day 3-5 (late) are shown in Table 2 . Of the 99 APAP-ALF nonsurvivors, 87 had data available at a late time point (12 died before day 3-5). Late APAP-ALF survivors (n 5 99) had significantly lower serum INR (1.5 versus 2.5), bilirubin (5.5 versus 9.8 mg/dL), creatinine (1.2 versus 2.4 mg/dL), and lactate (1.7 versus 3.8 mmol/L) levels compared to nonsurvivors (n 5 87). APAP-ALF survivors also demonstrated significantly lower late MELD scores (14 versus 30, P < 0.0001) than nonsurvivors. At late time points, survivors were significantly less likely to be on MV (49% versus 85%, P < 0.0001) and vasopressors (5% versus 52%, P < 0.0001) or to achieve high HE grade (59% versus 88%, P < 0.0001).
Late (days 3-5) levels of FABP1 are shown in Table  2 and graphically in Fig. 1 . APAP-ALF survivors had Abbreviations: CT, computed tomography; CXR, chest X-ray; ICP, intracranial pressure; ICU, intensive care unit; n, frequency.
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significantly lower late serum FABP1 levels (148.4 versus 612.3 ng/mL) compared with nonsurvivors (P < 0.0001). FABP1 levels were significantly higher in all ALF patients (survivors and nonsurvivors) compared to healthy controls for both early and late time points (P < 0.0001, data not shown).
MULTIVARIABLE ANALYSIS: ASSOCIATIONS WITH 21-DAY MORTALITY
In order to adjust for covariates, multivariable logistic regression for 198 APAP-ALF to determine associations (adjusted) with 21-day mortality were performed (Table 3 ). Two models were derived: one on admission (early) and one at day 3-5 (late). Values of serum FABP1 were transformed to their natural logarithm (log FABP1) to comply with the linearity assumption in logistic regression.
Early (Admission) Model
After adjusting for covariates, the multivariable early model included requirement for vasopressors (odds ratio [OR] 5 3.86, 95% confidence interval [CI] 1.65-9.07, P 5 0.0019), MELD (OR 5 1.042, 95% CI 1.004-1.082, per increment, P 5 0.03), and log FABP1 (OR 5 1.305, 95% CI 1.031-1.650, per unit, P 5 0.03). This model demonstrated an AUROC of 0.778. Plots of the relationship between early FABP1 levels and the adjusted OR of death at 21 days are shown in Supporting Fig. S3 . Early models including log FABP1 adjusting for RRT and creatinine separately demonstrated statistical significance for FABP1 (P < 0.0001 and 0.0001, respectively) but not for either RRT (P 5 0.61) or creatinine (P 5 0.48) (Supporting Table S1 ).
Late (Day 3-5) Model
After adjusting for covariates, the multivariable late Table S1 ).
INTERNAL VALIDATION: BOOTSTRAPPING
To internally validate the adjusted association between FABP1 and 21-day mortality, bootstrapping was performed to derive estimates for the early and late multivariable models presented in Table 3 (vasopressors, MELD, log FABP). Validation was done using 1,000 bootstrapped samples. Performances of both early (AUROC 0.778) and late (0.906) bootstrapped models were consistent with original multivariable models (Supporting Table S2 ).
Performance of KCC, ALFSG index, and FABP1: Early and Late
To determine the incremental benefit of FABP1 in addition to current scores in predicting 21-day mortality, performance characteristics of KCC, the ALFSG index (prognostic score), and FABP1 were calculated in early (n 5 198) and late (n 5 186) groups. Performance was also assessed for composite logistic regression models (KCC1FABP1, ALFSG index1FABP1). Data are shown in Table 4 .
On admission, AUROCs were 0.552 for KCC, 0.686 for ALFSG index, and 0.710 for FABP1. The AUROC for KCC1FABP1 was 0.711 and was significantly improved over KCC alone (P < 0.0001). The AUROC of ALFSG index1FABP1 was 0.766 and was significantly improved over ALFSG index alone (P 5 0.0008).
At late time points (day 3-5), AUROCs were 0.604 for KCC, 0.711 for ALFSG index, and 0.820 for FABP1. At late time points, 124 patients had complete data to calculate the ALFSG index. For those 124 patients, the AUROC of FABP1 alone (n 5 124) was 0.757, whereas the AUROC for ALFSG index-FABP1 was 0.815, which was significantly improved over that of the ALFSG index alone (P 5 0.0012). For 110 patients who had complete data to calculate the KCC, the AUROC of FABP1 alone (n 5 110) was 0.772. The AUROC for KCC1FABP1 was 0.797 and was significantly improved over KCC alone (P < 0.0001).
Performance of KCC, ALFSG index, and FABP1 Threshold: Early and Late
Based on maximizing the AUROC for both early and late time points, FABP1 values > 350 ng/mL were determined to be significantly associated with mortality. Performance was also assessed for composite logistic regression models using this threshold (KCC1 FABP1 > 350 ng/mL, ALFSG index1FABP1 > 350 ng/mL). Data are shown in Table 4 .
On admission, the AUROC for KCC1FABP1 > 350 ng/mL was 0.651 and was significantly improved over KCC alone (P 5 0.005). The AUROC of ALFSG index1FABP1 > 350 ng/mL was 0.720 and was not significantly improved over ALFSG index alone (P 5 0.077).
At late time points, 124 patients had complete data to calculate the ALFSG index. For those 124 patients, the AUROC of FABP1 > 350 ng/mL alone (n 5 124) was 0.746, whereas the AUROC for ALFSG index-FABP1 > 350 ng/mL was 0.818, which was significantly improved over that of the ALFSG index alone (P 5 0.0048). For 110 patients who had complete data to calculate the KCC, the AUROC of FABP1 > 350 ng/mL alone (n 5 110) was 0.760. The AUROC for KCC1FABP1 > 350 ng/mL was 0.794 and was significantly improved over that for KCC alone (P < 0.0001). Accuracy, sensitivity, and specificity and their 95% binomial CIs for KCC, ALFSG index, and FABP1 > 350 ng/mL are presented in Supporting  Table S3 .
Discussion
KEY RESULTS
In this nested case-control study of 198 APAP-ALF patients, we report the analysis of FABP1 in a large series of well-characterized APAP-ALF patients. Serum levels of FABP1 were significantly higher at early and late time points in APAP-ALF nonsurvivors. After adjusting for significant covariates reflecting severity of illness (MELD, vasopressor dependence), serum FABP1 (log) was significantly associated with 21-day mortality measured at both early (admission) and late (day 3-5) time points. Finally, FABP1 improved performance (AUROC) when used in combination with existing prognostic scores (KCC, ALFSG prognostic index). Serum FABP1 > 350 ng/ mL was associated with a significantly higher risk of death at early (P 5 0.0004) and late (P < 0.0001) time points. We specifically excluded patients who received LT to avoid the inevitable difficulty of assigning outcome in those rescued by transplantation and because protocols for deciding whether or not to transplant varied between enrolling ALFSG sites.
COMPARISON WITH THE LITERATURE
APAP-ALF represents the severest form of hepatic injury, resulting in massive necrosis. In the presence of hepatocyte injury, cytoplasmic proteins pass through large clefts embedded within a single endothelial cell layer and into the circulation. Hepatocyte damage results in FABP1 detection in blood (27) and has been proposed as a sensitive serum marker of hepatocellular damage in LT recipients. (28) Recently, FABP1 has been shown to be a diagnostic marker of liver injury in patients with hepatitis C infection (29) and to be associated with drug-induced liver injury. (30) However, to date FABP1 has not been evaluated as a prognostic marker in these conditions or ALF.
FABP1 has physiological properties that could potentially make it advantageous as a prognostic biomarker. It is present in high abundance in hepatocytes (approximately 2.7 mg/g of liver tissue) and has a lower molecular mass (14 kDa) and a shorter plasma half-life (11 minutes) compared to other cytosolic proteins (e.g., ALT). (31) This suggests FABP1 as a significantly more sensitive biomarker of hepatocyte necrosis compared to ALT (96 kDa and half-life of 40-60 minutes), an alternate marker of hepatocyte damage but with poor prognostic value in APAP-ALF (see Supporting Fig. S2 ). (27) Furthermore, alphaglutathione S-transferase has also been proposed as a potential biomarker of hepatocyte damage; however, its larger size (26 kDa) and relatively higher expression in kidney and intestine reduce its sensitivity and specificity. (28) Due to its low molecular mass, FABP1 levels in the serum are influenced by both renal function and RRT. FABP1 is present in significantly smaller quantities in the kidney (proximal tubules). (17, 32) It has been demonstrated in patients with cirrhosis that elevated levels of urinary FABP1 (but not serum) discriminate between patients with acute tubular necrosis and hepatorenal syndrome. (33) For this reason, it is important to adjust for renal dysfunction and renal support when assessing the prognostic discrimination of FABP1 in APAP-ALF patients. Multivariable analysis included the MELD score, which incorporates renal function (creatinine and presence of RRT) at both early and late time points and was significantly associated with 21-day mortality. RRT was not significantly associated with mortality (at early or late time points) after adjusting for covariates and therefore was excluded from the final models due to collinearity with MELD. After adjusting for MELD, FABP1 was nonetheless still significantly associated with 21-day mortality at both early and late time points. Furthermore, elevated FABP1 levels (early and late) were significantly associated with 21-day mortality after adjusting for the KCC, which also incorporate renal function (creatinine). Hence, the specificity of FABP1 for hepatic injury compared to the kidney and intestine may contribute to its potential discriminatory ability.
FABP1 is involved in uptake, transport, and metabolism of long-chain fatty acids. In addition, FABP1 has multiple biologic functions including roles in fatty acid transport, storage, and metabolism. (34) FABP1 also has an important role in facilitating hepatic fatty acid oxidation and is involved in trafficking and delivery of various ligands to cellular destinations such as enzymes, membranes, and nuclei. (35) FABP1 also acts as a cellular antioxidant as it contains a cysteine group and has been found to influence cell growth as it has been demonstrated to be elevated during stages of mitosis. (36) Hepatic long-chain fatty acid uptake is directly associated with FABP1 expression levels. (37) Therefore, increased expression of hepatocyte FABP1 could be a compensatory mechanism in an attempt to rescue energy-deprived hepatocytes undergoing necrosis. A failed attempt elicits necrosis, resulting in upregulated levels of FABP1 being released into the circulation. Studies have demonstrated that increased hepatocyte necrosis is associated with higher mortality in ALF. (38) Therefore, we speculate massive necrosis of hepatocytes containing overexpressed levels of FABP1 could justify the association with nonspontaneous hepatic recovery and explain the higher FABP1 levels found in nonsurvivors.
This study demonstrated that the addition of FABP1 to both the KCC and the ALFSG prognostic index significantly improved discrimination between 21-day survivors and nonsurvivors when measured at both early and late time points. Use of the KCC alone in this study yielded AUROCs of 0.552 on admission and 0.604 at later time points. This is similar to results published recently for the entire ALFSG cohort (AUROC 5 0.56 on admission). (5, 9) McPhail and colleagues recently demonstrated in a meta-analysis that the pooled sensitivity of the KCC in APAP-ALF was 58%. (39) Adding FABP1 to KCC significantly improved prognostic discrimination at both early (AUROC: KCC alone 0.552, 0.711 with FABP1) and late (0.604, 0.815 with FABP1) time points. Similar improvements were noted when adding FABP1 to the ALFSG prognostic index (ALFSG index, AUROC early alone, 0.686, 0.766 with FABP1; late alone 0.711, 0.815 with FABP1). KCC and ALFSG prognostic scores rely on markers of synthetic hepatic function (INR, bilirubin), HE (ALFSG index), renal dysfunction (MELD), and organ support (vasopressors, ALFSG index). Potentially, FABP1 may add discriminatory and prognostic information regarding hepatic injury or recovery that is not captured by these other covariates.
LIMITATIONS
The following limitations of this study warrant consideration. It is a nested case-control study, and as such, the event rate of the primary outcome (21-day mortality) was 50%, higher than published in cohort series. Although patients were enrolled and samples were collected prospectively, analysis was done retrospectively and therefore can comment on association and discrimination (between survivors and nonsurvivors) and not on the absolute risks of death according to serum FABP1 levels. To account for potential confounding in the study design, we performed multivariable analysis to adjust for other significant covariates (MELD, vasopressors, KCC, ALFSG prognostic index), which demonstrated FABP1 as a statistically significant discriminatory biomarker after adjusting for covariates. To avoid confounding related to LT because transplant listing decisions for APAP-ALF and the organ availability were not consistent between study centers (Simmons et al., ALFSG unpublished data), samples from patients who received LT were not evaluated in this study. The case-control design of the study may have introduced selection bias as the primary outcome of survival is automatically unbalanced within the clinical profile of the groups. However, in an attempt to reduce observation bias, data were collected prospectively; and within this specific study design, researchers measuring FABP1 were blinded to the clinical and outcome data of patients at the time of patient selection and sample analysis. We did not have access to a control group with critical illness but not APAP-ALF as a comparator to elucidate the association between FABP1 and critical illness. Validation was performed with bootstrapping as independent external samples were unavailable. The relationship of FABP1 and outcomes in ALF should be validated by external samples. Nonetheless, despite these limitations, we believe these results are robust as they include APAP-ALF cases from across 16 tertiary LT centers comprising the ALFSG and the statistically significant associations between FABP1 with mortality after adjusting for significant covariates (MELD, vasopressors) and known prognostic scores (KCC, ALFSG index).
In conclusion, in patients with APAP-ALF, FABP1 may have good potential to discriminate survivors from nonsurvivors and may improve models currently used in clinical practice. Validation of FABP1 as a clinical prediction tool in APAP-ALF warrants further investigation.
